Moderna (MRNA.US) started the week with an exceptionally dismal session, with a stock declining around 20%. Investors are selling off shares of the mRNA vaccine producer following the downward revision of its 2025 sales forecast by a full billion dollars.
Moderna expects revenue of between $1.5 billion and $2.5 billion in 2025, on average 30% below analysts' consensus. To improve profitability, CEO Stéphane Bancel announced a reduction in operational costs by $1 billion in 2025 and an additional $500 million in savings in 2026
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
The company’s forecasts have raised concerns about its profitability and competitiveness in the tight pharmaceutical market. Disappointing projections are primarily driven by the weak market adoption of its latest RSV vaccine and a continued decline in demand for COVID-19 vaccines. There is also little enthusiasm for the portfolio of currently developed projects, such as the CMV vaccine, which has so far failed to achieve planned efficacy in a clinical trial ongoing since 2021, or the combined COVID-19 and flu vaccine, which is still awaiting approval from the U.S. Food and Drug Administration (FDA).
MRNA.US (W1)
Although Moderna aligns with the overall downward trend observed among other biotech companies known from the pandemic era (e.g., Pfizer, marked in gray), its shares are losing value at an exceptionally fast pace. In 2024, the company’s shares lost about 60%, and an RSI below 30 indicates oversold conditions.
Source: xStation5
